Cohance Lifesciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


18,416	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
315	315	277	821	484
123	123	144	—	—
170	170	78.1	38.6	69.2
18,393	—	—	—	—
−146	−146	−199	−783	−415
₹480.74	—	—	—	—

4,204	4,204	1,919	2,089	1,804
4.0%	4.0%	4.1%	1.8%	3.8%
0.01×	—	—	—	—

8.59×	—	—	—	—
58.18×	—	—	—	—
147.84×	—	—	—	—
123.91×	—	—	—	—
2,142	2,269	1,198	1,051	1,340
316	427	375	406	567
124	240	298	351	519
—	368	288	358	451
148	148	132	307	165
—	144	132	305	164
—	220	156	51.8	286

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	18,416.5
- Cash, Equiv & ST Investments	483.7	821.1	277.1	315.5	315.5
+ Minority Interest	—	—	144.1	122.5	122.5
+ Total Debt	69.2	38.6	78.1	169.7	169.7
Enterprise Value	—	—	—	—	18,393.2
Net Debt (memo)	-414.6	-782.6	-199.0	-145.8	-145.8
EV per Share	—	—	—	—	480.74

Total Capital	1,804.3	2,089.2	1,918.8	4,203.5	4,203.5
Total Debt/Total Capital	3.83	1.85	4.07	4.04	4.04
Total Debt/EV	—	—	—	—	0.01

EV/Sales	—	—	—	—	8.59
EV/EBITDA	—	—	—	—	58.18
EV/EBIT	—	—	—	—	147.84
EV/Free Cash Flow	—	—	—	—	123.91
Reference Items — Trailing FY Values
Sales	1,340.3	1,051.4	1,197.6	2,268.6	2,141.5
EBITDA	566.5	405.8	375.2	427.0	316.1
EBIT	518.8	351.2	297.7	239.7	124.4
Operating Cash Flow	450.9	358.5	288.2	368.3	—
Free Cash Flow	165.1	306.7	132.5	148.4	148.4
FCFF (free cash flow to the firm)	163.7	304.8	131.6	144.0	—
Capital Expenditure	285.8	51.8	155.7	219.9	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.